Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer

BACKGROUND: Lucitanib is an oral, potent, selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1‒3, fibroblast growth factor receptors 1‒3, and platelet-derived growth factor receptors alpha/beta. OBJECTIVE: We aimed to develop a population pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Mingxiang, Zhou, Jie, Wride, Kenton, Lepley, Denise, Cameron, Terri, Sale, Mark, Xiao, Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399017/
https://www.ncbi.nlm.nih.gov/pubmed/35844029
http://dx.doi.org/10.1007/s13318-022-00773-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399017/
https://www.ncbi.nlm.nih.gov/pubmed/35844029
http://dx.doi.org/10.1007/s13318-022-00773-w

Ejemplares similares